Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Nephros (NEPH) EPS (Weighted Average and Diluted) (2022 - 2025)

Nephros has reported EPS (Weighted Average and Diluted) over the past 9 years, most recently at $0.01 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.01 for Q4 2025, down 75.0% from a year ago — trailing twelve months through Dec 2025 was $0.11 (up 1000.0% YoY), and the annual figure for FY2025 was $0.11, up 1000.0%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.01 at Nephros, down from $0.03 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for NEPH hit a ceiling of $0.05 in Q1 2025 and a floor of -$0.38 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.02 (2023), compared with a mean of -$0.05.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 350.0% in 2025, while the deepest fall reached 75.0% in 2025.
  • Nephros' EPS (Weighted Average and Diluted) stood at -$0.38 in 2022, then surged by 84.21% to -$0.06 in 2023, then skyrocketed by 166.67% to $0.04 in 2024, then plummeted by 75.0% to $0.01 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.01 (Q4 2025), $0.03 (Q3 2025), and $0.02 (Q2 2025) per Business Quant data.